Engineers Gate Manager LP Makes New Investment in Zimmer Biomet Holdings, Inc. $ZBH

Engineers Gate Manager LP acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 71,574 shares of the medical equipment provider’s stock, valued at approximately $6,162,000.

A number of other hedge funds and other institutional investors have also modified their holdings of ZBH. Main Management ETF Advisors LLC grew its stake in shares of Zimmer Biomet by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock worth $986,000 after purchasing an additional 112 shares in the last quarter. Citizens National Bank Trust Department lifted its holdings in Zimmer Biomet by 17.6% during the 1st quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 141 shares during the last quarter. TD Private Client Wealth LLC boosted its position in shares of Zimmer Biomet by 15.3% during the 4th quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider’s stock worth $104,000 after acquiring an additional 153 shares in the last quarter. Leonteq Securities AG increased its holdings in shares of Zimmer Biomet by 5.3% in the 1st quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider’s stock valued at $277,000 after acquiring an additional 153 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its holdings in shares of Zimmer Biomet by 5.5% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 3,133 shares of the medical equipment provider’s stock valued at $282,000 after acquiring an additional 162 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently weighed in on ZBH. Weiss Ratings upgraded Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, August 4th. Robert W. Baird set a $104.00 price target on shares of Zimmer Biomet in a research note on Thursday, August 6th. UBS Group reissued a “buy” rating and set a $120.00 price objective on shares of Zimmer Biomet in a report on Thursday, August 6th. Truist Financial upped their target price on shares of Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a report on Thursday, August 6th. Finally, Canaccord Genuity Group increased their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research report on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and a consensus price target of $104.42.

Insider Transactions at Zimmer Biomet

In related news, insider Chad Phipps sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the sale, the insider directly owned 65,231 shares in the company, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Trading Up 1.1%

Shares of Zimmer Biomet stock opened at $93.47 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $106.88. The company has a market capitalization of $17.83 billion, a P/E ratio of 22.74, a P/E/G ratio of 1.75 and a beta of 0.47. The business has a 50 day moving average price of $95.54 and a 200 day moving average price of $91.52.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter in the prior year, the firm earned $2.07 EPS. Zimmer Biomet’s quarterly revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.